Several medications are currently the subject of **class action lawsuits**, reflecting growing concerns about their safety, side effects, or corporate conduct related to their marketing and manufacturing. These lawsuits often involve large groups of plaintiffs who allege harm from the drugs and seek compensation or changes in how the drugs are handled. Here is an extensive overview of some of the most prominent medications facing such legal challenges as of 2025:
—
**Zantac (Ranitidine)**
Zantac, a popular heartburn medication, has been at the center of extensive litigation due to contamination with NDMA, a probable carcinogen. The lawsuits claim that long-term use of Zantac caused various cancers, including colorectal cancer. The litigation has been complex, with some major pharmaceutical companies like GlaxoSmithKline settling approximately 80,000 lawsuits for an estimated $2.2 billion. However, other defendants such as Boehringer Ingelheim continue to fight claims in court. The litigation has seen mixed results, with some trials ending in favor of defendants or no verdicts, reflecting the challenges plaintiffs face in proving causation and corporate liability. Despite setbacks, new lawsuits continue to be filed, and the legal battle remains active[1][6].
—
**Oxbryta (Voxelotor)**
Oxbryta, a drug used to treat sickle cell disease, was voluntarily withdrawn from the market in 2024 after post-marketing data revealed serious safety concerns, including increased rates of vaso-occlusive crises (VOCs) and deaths. Pfizer, which acquired the drug through its purchase of Global Blood Therapeutics, faces multiple lawsuits from patients and families alleging wrongful injury and death linked to Oxbryta. In 2025, a federal judge ordered formal settlement negotiations, signaling the litigation is moving toward potential resolution. The failure of Pfizer’s follow-up sickle cell drug trials has intensified scrutiny on the company’s sickle cell portfolio and its handling of Oxbryta’s risks[2].
—
**Trulicity and Other GLP-1 Drugs**
Trulicity, a widely prescribed GLP-1 receptor agonist used for type 2 diabetes and weight loss, has been linked to serious side effects such as gastroparesis—a condition where the stomach cannot empty properly. Since early 2025, over 1,800 lawsuits have been filed in multidistrict litigation against Eli Lilly and other manufacturers of GLP-1 drugs, alleging harm from these medications. The litigation is growing rapidly as more patients report severe complications. Hearings have been held to establish diagnostic criteria for gastroparesis in this context, and expert testimonies are being gathered to support the claims. The lawsuits focus on whether the companies adequately warned patients and healthcare providers about these risks[3].
—
**Valsartan and Other ARBs (Angiotensin Receptor Blockers)**
Valsartan, along with related drugs like losartan and irbesartan, has been involved in lawsuits due to contamination with NDMA and related carcinogens. These drugs are commonly prescribed for hypertension and heart failure. As of September 2025, over 1,300 valsartan lawsuits are pending in a multidistrict litigation in New Jersey. Plaintiffs allege that the manufacturers failed to ensure the safety of the drugs and that exposure to the contaminants increased cancer risk. No settlements or jury verdicts have been finalized yet, but bellwether trials are scheduled to test key issues in the litigation[5].
—
**Jasper Therapeutics’ Briquilimab**
Jasper Therapeutics, a biopharmaceutical company, faces a class action lawsuit related to its drug briquilimab, which was under investigation for several conditions including chronic spontaneous urticaria and asthma. In mid-2025, Jasper disclosed problems with a specific drug lot that affected clinical trial results, leading to halting of certain studies and development programs. The company’s stock pric
